 Connection
Corey Montgomery to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Corey Montgomery has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.086 |
|
|
|
-
Sabol HM, Paxton BC, Anloague A, Kaur J, Nester MR, Khan S, Smith J, Croucher PI, McDonald MM, Montgomery CO, Stambough JB, Barnes CL, Ambrogini E, Ebetino FH, Schinke C, Ashby C, Delgado-Calle J. Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. J Exp Clin Cancer Res. 2026 Jan 05; 45(1):31.
Score: 0.057
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|